A Case of Multisystem Inflammatory Syndrome in a Three-Year-Old Boy

Yazeid Alrefaey1, Abdulaziz F Alharbi1, Yazeed M Alzahrani2

  • 1Medical School, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Makkah, SAU.

Cureus
|August 1, 2022
PubMed

Insights

Multisystem inflammatory syndrome in children (MIS-C) following COVID-19 infection presents with diverse symptoms. Early diagnosis and treatment, like IVIG, lead to good outcomes in pediatric patients.

Area of Science:

  • Pediatric infectious diseases
  • Critical care medicine
  • Rheumatology

Background:

  • Multisystem inflammatory syndrome in children (MIS-C) is a serious condition linked to COVID-19.
  • It typically manifests with systemic inflammation and multi-organ involvement post-SARS-CoV-2 infection.

Observation:

  • A previously healthy 3-year-old boy presented with fever and diarrhea.
  • He tested positive for COVID-19 and showed laboratory markers of inflammation, including lymphopenia, thrombocytopenia, elevated INR, PT, and PTT.
  • Chest X-ray revealed bilateral peribronchial thickening.

Findings:

  • The patient received intravenous immunoglobulin (IVIG) and supportive care.
  • Clinical improvement was observed with a decrease in inflammatory markers.
  • The case highlights the effectiveness of timely intervention for MIS-C.

Implications:

  • MIS-C, despite its severity, generally has a favorable prognosis with appropriate management.
  • Clinicians must stay updated on MIS-C guidelines for accurate diagnosis and treatment.
  • Prompt management can prevent long-term sequelae in affected children.